<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doses and common adverse effects of medications used to treat nontuberculous mycobacterial (atypical mycobacterial) infections in children and adolescents&lt;SUP&gt;[1-6]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doses and common adverse effects of medications used to treat nontuberculous mycobacterial (atypical mycobacterial) infections in children and adolescents<sup>[1-6]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Doses and common adverse effects of medications used to treat nontuberculous mycobacterial (atypical mycobacterial) infections in children and adolescents<sup>[1-6]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="15%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Dose</td> <td class="subtitle1">Route</td> <td class="subtitle1">Usual maximum daily dose</td> <td class="subtitle1">Potential adverse effects and target dose ranges</td> </tr> <tr class="divider_bottom"> <td>Amikacin*<sup>¶</sup></td> <td> <ul> <li>15 to 22.5 mg/kg daily or divided in 2 to 3 doses </li> <li>15 to 25 mg/kg per day in 1 dose for 3 times per week dosing<sup>Δ</sup></li> </ul> </td> <td>IV, IM</td> <td> <ul> <li>1.5 g/day </li> </ul> </td> <td> <ul> <li>Dizziness; ataxia; vertigo; tinnitus; hearing loss; nephrotoxicity</li> <li>For every 8 hour dosing*: Adjust dose for trough &lt;3 to 5 mcg/mL and peak 20 to 25 mcg/mL</li> <li>For once daily dosing*: Adjust dose for trough 0.5 to 1 mcg/mL (at 18 hours) and peak 40 to 50 mcg/mL</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Azithromycin</td> <td> <ul> <li>5 to 10 mg/kg per day in 1 dose for daily dosing</li> <li>10 mg/kg per day in 1 dose for 3 times per week dosing</li> </ul> </td> <td>Oral, IV</td> <td> <ul> <li>Daily: 300 mg/day</li> <li>3 times per week: 500 mg/day </li> </ul> </td> <td> <ul> <li>Prolongation of the QT interval; nausea; vomiting; diarrhea; decreased hearing; dizziness; hepatitis; phlebitis (IV)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Cefoxitin<sup>¶</sup></td> <td> <ul> <li>160 mg/kg per day divided in 4 doses</li> </ul> </td> <td>IV, IM</td> <td> <ul> <li>12 g/day </li> </ul> </td> <td> <ul> <li>Bone marrow suppression; interstitial nephritis; hypersensitivity (fever, rash); may interfere with serum creatinine assay (falsely elevates creatinine)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Ciprofloxacin<sup>¶</sup></td> <td> <ul> <li>20 mg/kg per day divided in 2 doses</li> </ul> </td> <td>Oral, IV</td> <td> <ul> <li>Oral: 1.5 g/day </li> <li>IV: 1200 mg/day </li> </ul> </td> <td> <ul> <li>Tendon damage; prolongation of the QT interval; CNS stimulation; nausea; vomiting; diarrhea</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Clarithromycin<sup>¶</sup></td> <td> <ul> <li>15 to 30 mg/kg per day divided in 2 doses (for daily or 3 times per week dosing)<sup>Δ</sup></li> </ul> </td> <td>Oral</td> <td> <ul> <li>1 g/day </li> </ul> </td> <td> <ul> <li>Prolongation of the QT interval; nausea; vomiting; diarrhea; taste disturbance; decreased hearing; hepatitis<sup>◊</sup>; anterior uveitis<sup>◊</sup>; arthralgia<sup>◊</sup>; granulocytopenia<sup>◊</sup>; significant drug-drug interactions (particularly with rifamycins)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Doxycycline</td> <td> <ul> <li>2 to 4 mg/kg per day in 1 or 2 doses</li> </ul> </td> <td>Oral, IV</td> <td> <ul> <li>200 mg/day </li> </ul> </td> <td> <ul> <li>Tooth discoloration in children &lt;8 years; nausea; vomiting; diarrhea; photosensitivity; rash; hyperpigmentation; phlebitis (IV); and injection site pain (IV)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Ethambutol<sup>¶</sup></td> <td> <ul> <li>15 mg/kg per day in 1 dose for daily dosing</li> <li>25 mg/kg per day in 1 dose for 3 times per week dosing<sup>Δ</sup></li> </ul> </td> <td>Oral</td> <td> <ul> <li>Daily: 1 g/day </li> <li>3 times per week: 2.5 g/day </li> </ul> </td> <td> <ul> <li>Optic neuritis (usually reversible)<sup>§</sup>; red-green color blindness<sup>¥</sup>; gastrointestinal disturbances; hypersensitivity</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Imipenem<sup>¶</sup></td> <td> <ul> <li>60 to 100 mg/kg per day in 4 doses</li> <li>Adolescents can receive 500 mg to 1 g 2 or 3 times daily</li> </ul> </td> <td>IV</td> <td>4 g/day</td> <td> <ul> <li>Nausea; vomiting; diarrhea; hypersensitivity; seizures; confusion; hepatitis; leukopenia; anemia; thrombocytopenia</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Isoniazid</td> <td> <ul> <li>5 mg/kg per day for NTM infection</li> <li>10 to 15<sup>‡ </sup>mg/kg per day in 1 dose if cannot definitively exclude <span style="font-size: 10pt; font-family: 'Verdana',sans-serif;"><em>Mycobacterium</em></span><em> tuberculosis</em></li> </ul> </td> <td>Oral, IM</td> <td> <ul> <li>300 mg/day </li> </ul> </td> <td> <ul> <li>Mild hepatic enzyme elevation; hepatitis<sup>‡</sup>; peripheral neuritis; hypersensitivity (fever, rash); diarrhea and gastric irritation (caused by vehicle in syrup)</li> <li>Pyridoxine supplementation of 1 to 2 mg/kg per day (up to 50 mg/day) is suggested to prevent peripheral neuropathy in exclusively breastfed infants, children and adolescents on meat- and milk-deficient diets, children with nutritional deficiencies, children and adolescents with symptomatic HIV infection, and pregnant adolescents</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Levofloxacin<sup>¶</sup></td> <td> <ul> <li>&lt;5 years: 20 mg/kg per day in 2 doses</li> <li>≥5 years: 10 mg/kg once daily</li> </ul> </td> <td>Oral, IV</td> <td> <ul> <li>500 mg/day </li> </ul> </td> <td> <ul> <li>Tendon damage; CNS stimulation; nausea; vomiting; diarrhea</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Linezolid</td> <td> <ul> <li>&lt;12 years: 30 mg/kg per day in 3 doses</li> <li>≥12 years: 600 mg twice per day</li> </ul> </td> <td>Oral, IV</td> <td> <ul> <li>1200 mg/day </li> </ul> </td> <td> <ul> <li>Nausea; vomiting; diarrhea; leukopenia; anemia; thrombocytopenia; pancytopenia; peripheral neuropathy; optic neuritis; serotonin syndrome</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Meropenem<sup>¶</sup></td> <td> <ul> <li>&lt;50 kg: 30 to 60 mg/kg per day divided in 3 doses</li> <li>≥50 kg: 3 g/day in 3 divided doses</li> </ul> </td> <td>IV</td> <td> <ul> <li>3 g/day </li> </ul> </td> <td> <ul> <li>May lower seizure threshold; bone marrow suppression; interstitial nephritis</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Moxifloxacin</td> <td> <ul> <li>400 mg per day in 1 dose (for adolescents)</li> </ul> </td> <td>Oral</td> <td> <ul> <li>400 mg/day </li> </ul> </td> <td> <ul> <li>Tendon damage; CNS stimulation; nausea; vomiting; diarrhea</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Pyrazinamide<sup>¶</sup></td> <td> <ul> <li>30 to 40 mg/kg per day for daily dosing</li> <li>50 mg/kg per day for twice weekly dosing</li> </ul> </td> <td>Oral</td> <td> <ul> <li>2 g/day </li> </ul> </td> <td> <ul> <li>Arthralgia; gastrointestinal tract upset; hepatotoxicity; hyperuricemia </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Rifabutin<sup>¶</sup><sup>†</sup></td> <td> <ul> <li>10 to 20 mg/kg per day in 1 dose (for daily or 3 times per week dosing)</li> </ul> </td> <td>Oral</td> <td> <ul> <li>300 mg/day </li> </ul> </td> <td> <ul> <li>Orange discoloration of secretions (may stain soft contact lenses), urine, and stool; gastrointestinal disturbance; hepatitis<sup>◊</sup>; "flu-like" syndrome; thrombocytopenia; renal failure; myalgia; arthralgia<sup>◊</sup>; granulocytopenia<sup>◊</sup>; anterior uveitis<sup>◊</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Rifampin (rifampicin)<sup>†</sup></td> <td> <ul> <li>15 to 20 mg/kg per day in 1 dose (for daily or 3 times per week dosing)</li> </ul> </td> <td>Oral, IV</td> <td> <ul> <li>Children weighing &lt;50 kg: 450 mg/day</li> <li>Children weighing ≥50 kg: 600 mg/day </li> </ul> </td> <td> <ul> <li>Orange discoloration of secretions (may stain soft contact lenses), urine, and stool; gastrointestinal disturbance; hepatitis; "flu-like" syndrome; thrombocytopenia; renal failure; multiple significant drug-drug interactions</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Streptomycin*<sup>¶</sup></td> <td> <ul> <li>20 to 40 mg/kg per day in 1 dose or in 2 divided doses (preferred for IV)</li> <li>15 to 25 mg/kg per day in 1 dose for 3 times per week dosing<sup>Δ</sup></li> </ul> </td> <td>IM, IV (if IM not tolerated)</td> <td> <ul id="_telerik_insertedList_id"> <li>1 g/day </li> </ul> </td> <td> <ul> <li>Dizziness; ataxia; vertigo; tinnitus; hearing loss; nephrotoxicity; hypersensitivity reaction</li> <li>Adjust dose for trough &lt;3 to 5 mcg/mL and peak 15 to 30 mcg/mL for every 12 hour dosing*</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Tigecycline</td> <td> <ul> <li>8 to 11 years: 2.4 to 4 mg/kg per day in 2 divided doses</li> <li>≥12 years: 50 mg every 12 hours</li> </ul> <p> </p> </td> <td>IV</td> <td> <ul> <li>100 mg/day</li> </ul> </td> <td> <ul> <li>Nausea; anorexia; vomiting; diarrhea; photosensitivity; coagulopathy; tooth discoloration (in children &lt;8 years of age); phlebitis; injection site pain</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Tobramycin*<sup>¶</sup></td> <td> <ul> <li>7.5 mg/kg per day in 3 doses or 7 mg/kg once daily</li> </ul> </td> <td>IM, IV</td> <td> <ul> <li>300 mg/day </li> </ul> </td> <td> <ul> <li>Dizziness; ataxia; vertigo; tinnitus; hearing loss; nephrotoxicity</li> <li>For every 8 hour dosing*: Adjust dose for trough &lt;1 mcg/mL and peak 6 to 8 mcg/mL</li> <li>For once daily dosing*: Adjust dose for trough &lt;1 mcg/mL at 18 hours and peak 15 to 22 mcg/mL</li> </ul> </td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole<sup>¶</sup><br/> (TMP-SMX, cotrimoxazole)</td> <td> <ul> <li>8 to 12 mg/kg per day of the TMP component divided in 2 doses</li> </ul> </td> <td>Oral, IV</td> <td> <ul> <li>320 mg/day of TMP component </li> </ul> </td> <td> <ul> <li>Rash; hypersensitivity reaction (fever, rash, Stevens-Johnson syndrome); bone marrow suppression; nausea; vomiting; diarrhea; IV formulation requires substantial dilution, which may result in large volumes (which may be problematic for patients with renal insufficiency or fluid overload)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Combinations of 2 to 4 of the above agents are selected based upon type of NTM infection and susceptibility testing. Consultation with a specialist in infectious diseases is recommended. Refer to UpToDate topics on NTM infections in children for details.</div><div class="graphic_footnotes">IV: intravenous; IM: intramuscular; CNS: central nervous system; NTM: nontuberculous mycobacterial infection (also known as atypical mycobacterial infection); HIV: human immunodeficiency virus.<br/>* Monitor drug levels to ensure efficacy and avoid toxicity. The targeted range varies depending upon the clinical syndrome, patient characteristics (eg, cystic fibrosis), and the institution. Consultation with an infectious diseases specialist or pharmacist regarding the appropriate therapeutic range is suggested. Aminoglycoside toxicity is dependent upon duration of treatment and aminoglycoside-free period of dosing interval. (Refer to UpToDate topic on aminoglycosides.)<br/>¶ Doses are for children with normal renal function.<br/>Δ Clinical data in adults indicate that 3 times weekly therapy is as effective as daily therapy, with reduced toxicity, for mild to moderate disease.<br/><font class="lozenge">◊</font> Anterior uveitis, arthralgia, neutropenia, and liver function abnormalities may occur when clarithromycin is used in combination with rifabutin.<br/>§ Usually reversible; rare at doses of 15 to 25 mg/kg in children with normal renal function.<br/>¥ Rarely occurs in children, who metabolize ethambutol more rapidly than adults.<br/>‡ The incidence of hepatotoxicity may be increased when isoniazid doses &gt;10 mg/kg are used in combination with rifampin.<br/>† Dose may require modification based upon drug-drug interactions, particularly with clarithromycin<font color="black">. Many experts recommend a daily dose of at least 20 mg/kg per day for infants and toddlers and for serious tuberculosis disease (eg, meningitis, disseminated disease). </font></div><div class="graphic_reference">References: 

<ol>
<li><font color="black">American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.876.</font></li>
<li><font color="black">American Academy of Pediatrics. Tuberculosis. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.786.</font></li>
<li><font color="black">Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: Literature review and recommendations. Int J Tuberc Lung Dis 2006; 10:1318.</font></li>
<li><font color="black">Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</font></li>
<li><font color="black">Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis 2020; 71:e1.</font></li>
<li><font color="black">Department of Health and Human Services. Panel on opportunistic infections in HIV-exposed and HIV-infected children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Mycobacterium avium complex disease. Available at: <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/mycobacterium-avium-complex-disease" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/mycobacterium-avium-complex-disease</a>. Accessed on June 16, 2021.</font></li></ol></div><div id="graphicVersion">Graphic 86161 Version 20.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
